Cancer treatment is entering a new era. Peptide radionuclide therapy, also called PRRT, is giving doctors a powerful new tool to fight tumors with precision.
- PRRT uses peptides to deliver radiation directly to cancer cells
- This approach causes less damage to healthy tissue than traditional radiation
- The FDA approval of Lutathera in 2018 opened the door for many new PRRT drugs
- Clinical trials are now testing PRRT for prostate, breast, and other cancers
- The radiopharmaceutical market is growing fast, creating new workforce needs
What Is Peptide Radionuclide Therapy?
PRRT combines two things: a peptide that finds cancer cells and a radioactive atom that kills them. The peptide acts like a GPS system, guiding the radiation right to the tumor.
Once the peptide attaches to the cancer cell, the radioactive part delivers a strong dose of radiation. This destroys the cancer cell while leaving nearby healthy cells mostly untouched.
How PRRT Works Step by Step
The process starts with a diagnostic scan. Doctors inject a small amount of the peptide with a tracer attached to see if your tumor has the right receptors.
If the scan shows the tumor lights up, you are a good candidate for PRRT. The treatment version uses a stronger radioactive atom that kills the cells instead of just imaging them.
The Treatment Process
Patients typically receive PRRT as an infusion in a hospital or clinic. Each session takes a few hours, and most treatment plans include four to six sessions spread over several months.
After the infusion, the peptide travels through your blood and finds the tumor cells. The radiation does its work over the following days and weeks.
According to the American Society of Clinical Oncology, patients with neuroendocrine tumors treated with Lutathera (a PRRT drug) had a 79% lower risk of disease progression compared to standard treatment. This was a landmark finding that changed how doctors treat these cancers.
The Growth of PRRT in Oncology
PRRT started with neuroendocrine tumors, a rare cancer type. But now researchers are testing it against many other kinds of cancer.
The success of Lutathera showed the medical world that this approach works. Now, dozens of companies and research teams are racing to create new PRRT drugs.
Cancers Being Targeted by PRRT
| Cancer Type | Target Receptor | Development Stage |
|---|---|---|
| Neuroendocrine tumors | Somatostatin receptors | FDA approved (Lutathera) |
| Prostate cancer | PSMA | Late-stage trials |
| Breast cancer | HER2 and others | Early-stage trials |
| Glioblastoma | Various peptide targets | Preclinical and Phase 1 |
| Pancreatic cancer | Somatostatin receptors | Phase 2 trials |
| Small cell lung cancer | Multiple targets | Preclinical |
Prostate Cancer and PSMA-Targeted Therapy
One of the biggest areas of growth is in prostate cancer. PSMA (prostate-specific membrane antigen) is a protein found on the surface of most prostate cancer cells.
Scientists have created peptides that bind tightly to PSMA. When linked to a radioactive atom like lutetium-177, these peptides deliver radiation straight to prostate tumors.
Expert Quote: "PRRT is doing for radiation therapy what targeted drugs did for chemotherapy. We are moving from a carpet-bombing approach to a precision strike.", Dr. James Harmon, Radiation Oncology Researcher
Key Advantages of PRRT Over Traditional Treatments
PRRT offers several benefits compared to surgery, chemotherapy, and external beam radiation. These advantages are driving its rapid adoption.
Precision targeting. The peptide finds the tumor no matter where it is in the body. This is especially helpful for cancers that have spread to multiple locations.
Fewer side effects. Because the radiation is delivered directly to cancer cells, healthy tissue gets less exposure. Patients often tolerate PRRT much better than chemotherapy.
Works on hard-to-reach tumors. Some tumors are in places where surgery is too risky. PRRT can reach these tumors through the bloodstream.
Repeatable treatment. Patients can receive multiple rounds of PRRT if needed. This is harder to do with surgery or high-dose external radiation.
Challenges Facing PRRT Expansion
Despite its promise, PRRT faces several challenges that must be solved for it to reach its full potential.
Supply Chain Issues
The radioactive atoms used in PRRT have short half-lives. Lutetium-177, for example, loses half its radioactivity in about 6.6 days.
This means the drug must be made, shipped, and given to the patient very quickly. Any delay in the supply chain can make the product useless.
Limited Treatment Centers
PRRT requires specialized facilities with radiation safety equipment and trained staff. Not every hospital can offer this treatment today.
Building more treatment centers takes time and money. Training the staff to work safely with radioactive materials is also a big challenge.
Manufacturing Complexity
Making PRRT drugs involves handling radioactive materials under strict safety and quality rules. This requires specialized equipment and highly trained workers.
Scaling up production to meet growing demand is one of the biggest challenges the industry faces right now.
| Challenge | Impact | Possible Solution |
|---|---|---|
| Short half-life of isotopes | Limits shipping distance | Build regional production sites |
| Few treatment centers | Limits patient access | Invest in facility expansion |
| Complex manufacturing | High production costs | Automate key production steps |
| Regulatory hurdles | Slows approval timelines | Harmonize global regulations |
| Workforce shortage | Limits capacity growth | Train more nuclear pharmacists |
The global radiopharmaceutical market is expected to grow from $8 billion in 2023 to over $17 billion by 2030. PRRT is one of the fastest-growing segments within this market.
The Workforce Behind PRRT
Running a PRRT program requires many different types of skilled workers. The demand for these professionals is growing fast.
Nuclear pharmacists prepare the radioactive drugs. They must follow strict safety rules and have special training in handling radioactive materials.
Radiation safety officers make sure the facility meets all safety standards. They monitor radiation levels and train other staff on safety procedures.
Nuclear medicine physicians oversee the treatment and interpret imaging results. They work closely with oncologists to plan each patient's care.
Radiochemists develop and optimize the processes for making PRRT drugs. They are essential for scaling up production.
New Isotopes and Next-Generation PRRT
Researchers are testing new radioactive atoms that could make PRRT even more powerful. Some of the most exciting ones include actinium-225 and lead-212.
These alpha-emitting isotopes release a different type of radiation that is even more destructive to cancer cells. Early results from clinical trials have been very promising.
Alpha vs. Beta Emitters
Most current PRRT drugs use beta-emitting isotopes like lutetium-177. Beta particles travel a short distance and damage cells in a small area.
Alpha-emitting isotopes are much more powerful but travel an even shorter distance. This means they can kill cancer cells while causing almost no damage to nearby healthy tissue.
The Business of PRRT
Major pharmaceutical companies are investing heavily in PRRT. Novartis paid $2.1 billion to acquire Advanced Accelerator Applications, the maker of Lutathera.
Other big players are also entering the market through acquisitions and partnerships. This level of investment shows how much confidence the industry has in PRRT's future.
Smaller biotech companies are also making waves with innovative PRRT platforms. Many of them are looking for skilled workers to grow their teams.
For companies building PRRT capabilities, having the right team is critical. Learn about recruiting formulation scientists to support your pipeline. You can also explore process chemistry outsourcing to accelerate your development timeline.
What Patients Should Know
If you or a loved one has been diagnosed with cancer, ask your doctor about PRRT. Not every cancer type is a good fit, but the list of treatable cancers is growing.
The first step is usually a diagnostic scan to see if your tumor has the right receptors. If it does, PRRT could be a significant option for you.
The Road Ahead
PRRT is still in its early chapters. As more clinical trials report positive results, we will see this therapy approved for more cancer types.
Better manufacturing methods and more treatment centers will make PRRT available to more patients around the world.
New combinations of PRRT with other treatments, like immunotherapy, are also being tested. These combination approaches could make both therapies more effective than either one alone.
Frequently Asked Questions
What types of cancer can be treated with PRRT?
Currently, PRRT is FDA-approved for certain neuroendocrine tumors. Clinical trials are testing it for prostate cancer, breast cancer, glioblastoma, and several other cancer types.
Is PRRT covered by insurance?
FDA-approved PRRT treatments like Lutathera are generally covered by most insurance plans. Experimental PRRT treatments in clinical trials may be covered by the trial sponsor.
What are the side effects of PRRT?
The most common side effects include nausea, fatigue, and temporary drops in blood cell counts. These are usually mild compared to the side effects of chemotherapy.
How many PRRT treatments does a patient need?
Most treatment plans include four to six infusion sessions, given about eight weeks apart. The exact number depends on the patient's response and the specific drug used.
Where can I get PRRT treatment?
PRRT is available at major cancer centers and hospitals with nuclear medicine departments. Ask your oncologist for a referral to a center that offers this therapy.
Topics
Amanda Foster
Peptide Industry Analyst
MS, Health Economics | 8 years in peptide market research
Tracks workforce trends, compensation data, and market dynamics across the peptide industry. Produces quarterly salary benchmarks and employer-of-record analysis cited by clinic operators nationwide.
Reviewed by Amanda Foster, MS, April 2026